We have recently shown that CD40L and IL-4 can inhibit NK cell activation against primary CLL cells via upregulation of HLA-E, the ligand for the NK cell inhibitory receptor NKG2A [23]. This evidence concerns the gene CD40LG and B-cell chronic lymphocytic leukemia.